<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05615012</url>
  </required_header>
  <id_info>
    <org_study_id>IM032-039</org_study_id>
    <nct_id>NCT05615012</nct_id>
  </id_info>
  <brief_title>A Study Investigating Interactions Between BMS-986322 and Rosuvastatin or Metformin in Healthy Participants</brief_title>
  <official_title>An Open-Label, Single-Sequence Crossover, Drug-Drug Interaction Study to Assess the Effect of Steady-State BMS-986322 on the Pharmacokinetics of Rosuvastatin (Part 1) or the Pharmacokinetics and Pharmacodynamics of Metformin (Part 2) in Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of coadministration of multiple oral doses of&#xD;
      BMS-986322 with rosuvastatin or metformin in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 10, 2022</start_date>
  <completion_date type="Anticipated">January 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])</measure>
    <time_frame>Up to 21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (T-HALF)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to 51 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to 51 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to 51 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to 51 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to 51 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Part 1: Rosuvastatin + BMS-986322</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Metformin + BMS-986322 + Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986322</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1: Rosuvastatin + BMS-986322</arm_group_label>
    <arm_group_label>Part 2: Metformin + BMS-986322 + Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1: Rosuvastatin + BMS-986322</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2: Metformin + BMS-986322 + Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glucose</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2: Metformin + BMS-986322 + Glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the investigator, a healthy participant, as determined by no&#xD;
             clinically significant deviation from normal in medical history, physical examination,&#xD;
             ECGs, and clinical laboratory determinations.&#xD;
&#xD;
          -  Body mass index (BMI) of 18.0 kilogram (kg)/meter(m)^2 to 30.0 kg/m^2, inclusive, and&#xD;
             body weight ≥ 50 kg for males and ≥ 45 kg for females, at screening.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is a woman not of childbearing&#xD;
             potential.&#xD;
&#xD;
          -  Female participants must refrain from donating oocytes during the intervention period&#xD;
             and for at least 5 half-lives (5 days) after the last dose of study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness.&#xD;
&#xD;
          -  Any major surgery, including any gastrointestinal (GI) surgery, with the exception of&#xD;
             appendectomy, within 90 days of study intervention administration.&#xD;
&#xD;
          -  History of alcohol abuse within 1 year prior to screening or regular use of alcohol&#xD;
             within 6 months prior to screening that exceeds 7 units for women or 14 units for men&#xD;
             of alcohol per week (1 unit = 340 mililitre [mL] of beer 5%, 140 mL of wine 12%, or 45&#xD;
             mL of distilled alcohol 40%).&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BMS Study Connect Contact Center www.BMSStudyConnect.com</last_name>
    <phone>855-907-3286</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site #.</last_name>
  </overall_contact_backup>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BMS-986322</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Metformin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

